Clinical Trials Logo

Clinical Trial Summary

This study is designed to collect parallel intracardiac signal data during pre-defined periods of clinical interest from the PURE EP system and the existing signal recording and mapping systems. The collected signals will then undergo BLINDED, CONTROLLED evaluation by unbiased electrophysiologist reviewer(s) to determine whether the PURE EP signals provides additional or clearer diagnostic information.


Clinical Trial Description

Cardiac electrophysiologists rely on the display of electrograms when performing electrophysiology (EP) studies and catheter ablations in patients with arrhythmias. To achieve effective outcomes without complications, it is vital that the recording system enables the recognition of clearly abnormal (scared myocardium) and normal electrical signals. Current recording systems have limitations in that it can be difficult to clearly distinguish a true cardiac signal from noise or artifact. This is particularly true when pacing the heart and when ablating abnormal myocardial tissue, components of the conduction system or epicardial structures. Therefore, improvement of the fidelity of signals obtained from EP recording systems is needed to enhance identification of the most effective targets for ablation. There are several standard electrophysiology recording systems in use today, such as the commonly used GE/Prucka CardioLab recording system ("Prucka") which would benefit from additional features in order to improve the ability to record, discriminate and analyze signals from the heart. BioSig Technologies, Inc. ("BioSig") has developed an electrophysiology signal processing system, the PURE EP™ System, which may allow electrophysiologists to better characterize arrhythmogenic tissue during ablation procedures. Specifically, the PURE EP™ System's higher sampling rate and higher dynamic range allow improved visualization of low amplitude signals, especially those temporally situated near low frequency, high amplitude signals or large high-frequency signals. This multi-center, prospective, non-randomized, observational study will involve at least five patients undergoing elective cardiac ablation procedure for tachycardias such as atrial fibrillation, atypical atrial flutter, ischemic ventricular tachycardia, or symptomatic premature ventricular contractions (PVCs). The existing recording/mapping system clocks will be synchronized to the PURE EP clock prior to each procedure. At the beginning of the procedures, all systems will be optimized for best signal display based on the physician preference. During the ablation procedures, annotations will be captured on the PURE EP system based on pre-determined clinically relevant events defined in this protocol (example - before and after successful ablation therapy). After the procedures, parallel signal data samples will be harvested from all the systems using the procedure annotations and the time stamps as a guide. Once the signal data is harvested, cleaned, and organized, the individual signal samples will be reviewed in a blinded, controlled fashion by a group of independent, unbiased electrophysiologist(s). Selected signal sample sets (from the same date and time stamp) will be separated in the survey and arranged in random order. The reviewer will be asked specific and identical questions relevant to each set of signal samples, but the individual samples will be separated and randomized across a full survey containing many different signal samples from many different procedures. The signal survey will be created under the direction of the Principle Investigator. The selection of the independent EP reviewers will also be done under the direction of the Principle Investigator ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04112433
Study type Observational
Source BioSig Technologies, Inc.
Contact
Status Completed
Phase
Start date November 12, 2019
Completion date January 29, 2022

See also
  Status Clinical Trial Phase
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)
Completed NCT02241252 - Using an iPhone ECG to Monitor the QT Interval on Dofetilide and Sotalol Patients N/A
Completed NCT01428778 - Berlin Beat of Running Study N/A
Completed NCT01626261 - Examination of Implant´s Safety in an Electronic and Magnetic Field Environment
Withdrawn NCT01359683 - Heart Rate Variability Changes During Cardiac Surgery And The Incidence Of Post-Operative Cardiac Arrhythmias N/A
Recruiting NCT04154982 - N-Acetylcysteine Protection Against Radiation Induced Cellular Damage Phase 2
Completed NCT04609683 - Measuring Hydration Levels of Healthy and Heart Failure Patients Before, During, and After an Electrophysiology (EP) Procedure N/A
Completed NCT04162249 - High Radiofrequency Power for Faster and Safer Pulmonary Veins Isolation - a Pilot Observational Study.
Withdrawn NCT05084391 - Phase I/II Randomized Study of Stereotactic Ablative Radiotherapy (SABR) Versus Standard of Care for Refractory Structural Cardiac Arrhythmias (SABR-HEART) Phase 1/Phase 2
Completed NCT03260244 - EnSite Precision Observational Study
Recruiting NCT04474418 - Psychometric Characterization of Patients With Cardiac Arrhythmias
Recruiting NCT03996954 - Validation of a Smartphone-based Recorder for Detection of Cardiac Arrhythmias N/A
Recruiting NCT05508880 - SIGIL: Signal Interpretation and Analysis In Real Life Cardiac Arrhythmias
Terminated NCT04552665 - Prospective Procedural Data Collection for Continuous Improvement of the KODEX - EPD™ System Performance.
Recruiting NCT06073509 - Atrial Fibrillation and Other Cardiac Arrhythmias and Diseases After Radiotherapy for Breast Cancer : Watch Your HeaRT
Completed NCT04463524 - Screening for Hearth Rhythm Disorders
Withdrawn NCT01394965 - Electrocardiographic Mapping and Imaging Phase 0
Completed NCT01672528 - Patient Reported Outcome Measures for Ablation of Cardiac Arrhythmias
Completed NCT02232204 - Sleep and Ventricular Arrhythmias Study Phase 2
Completed NCT05114382 - An Evaluation of the Safety and Performance of the CathVision Cube® System N/A